Chronic Myeloid Leukemia (CML) is a prototypic malignacy that can be controlled by targeted therapy. Patients nowadays have a normal life expectancy and a certain proportion of patients remain in remission after stopping their medication. Still, response kinetics and success rates vary, which can be attributed in part to differences in the immune system. According to our findings, the level of molecular response is associated with a certain level of inflammation, which can be predicted by plasma levels of soluble CD62L, an immune regulatory protein. Within this project, our mission is to undertake validating experiments in bigger patient cohorts to confirm the usefulness of CD62L as a marker of inflammation.